Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?
Read More Pharma Industry News Sarepta Therapeutics (NASDAQ: SRPT) hit by FDA boxed warning as ELEVIDYS loses non‑ambulatory DMD indication Sarepta’s ELEVIDYS gene therapy label now includes a boxed liver warning and removes non-ambulatory DMD use. Explore the safety updates and investor outlook. byVenkateshNovember 15, 2025